Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: August 4, 2011
Last updated: September 5, 2013
Last verified: May 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2011
  Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)